Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Tilray Announces One-for-Ten Reverse Stock Split

Tilray Brands, Inc. has recently announced the implementation of a one-for-ten reverse stock split, which is expected to be effective on December 1, 2025. This decision was previously approved at a special meeting of stockholders held on June 10, 2025.

As a result of the reverse stock split, the number of shares of the company's outstanding common stock will be reduced from approximately 1.16 billion shares to 116 million shares. Fractional shares will not be issued, and stockholders will receive cash in lieu of any fractional shares that would have been created by the reverse stock split.

The reverse stock split is expected to achieve several objectives, including aligning Tilray's number of shares outstanding with companies of similar size and scope, making the company more attractive to institutional shareholders, and reducing expenditures associated with the annual meeting of stockholders, resulting in up to $1 million in cost savings on an annual run rate basis.

Following the implementation of the reverse stock split, shares of the company's common stock will begin trading on a split-adjusted basis under the same symbol (TLRY) when the markets open on December 2, 2025, with the new CUSIP number of 88688T209.

Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America, supporting over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. Today the company's shares have moved 4.76% to a price of $1.03. For the full picture, make sure to review Tilray Brands's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS